Cargando…

Variability of FEV(1) and Criterion for Acute Pulmonary Exacerbation

Detalles Bibliográficos
Autores principales:	Jenkins, Bradlee A., Glenn, Loyd Lee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201084/ https://www.ncbi.nlm.nih.gov/pubmed/25368859 http://dx.doi.org/10.3389/fped.2014.00114

Ejemplares similares

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV(1) decline
por: de Aquino, Carolina Silva Barboza, et al.
Publicado: (2022)

Rhinovirus‐associated pulmonary exacerbations show a lack of FEV (1) improvement in children with cystic fibrosis
por: Cousin, Mathias, et al.
Publicado: (2016)

Time Free From Hospitalization in Children and Adolescents With Cystic Fibrosis: Findings From FEV(1), Lung Clearance Index and Peak Work Rate
por: Gambazza, Simone, et al.
Publicado: (2022)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

The Controversy Persists: Is There a Qualification Criterion to Utilize Inhaled Nitric Oxide in Pre-term Newborns?
por: Vieira, Frederico, et al.
Publicado: (2021)

Sputum cell counts to manage prednisone-dependent asthma: effects on FEV(1) and eosinophilic exacerbations
por: Aziz-Ur-Rehman, Afia, et al.
Publicado: (2017)

Metabolomic Biomarkers to Predict and Diagnose Cystic Fibrosis Pulmonary Exacerbations: A Systematic Review
por: Nguyen, Anna-Lisa V., et al.
Publicado: (2022)

Cut-off value of FEV(1)/FEV(6) as a surrogate for FEV(1)/FVC for detecting airway obstruction in a Korean population
por: Chung, Kyung Soo, et al.
Publicado: (2016)

Genome organization and molecular characterization of the three Formica exsecta viruses—FeV1, FeV2 and FeV4
por: Dhaygude, Kishor, et al.
Publicado: (2019)

Cut-off value of FEV(1)/FEV(6) to determine airflow limitation using handheld spirometry in subjects with risk of chronic obstructive pulmonary disease
por: Hwang, Yong Il, et al.
Publicado: (2021)

Pulmonary function testing in COPD: looking beyond the curtain of FEV1
por: Kakavas, Sotirios, et al.
Publicado: (2021)

Effects of Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study
por: Zendedel, Abolfazl, et al.
Publicado: (2015)

Longitudinal change of FEV(1) and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD
por: Jo, Yong Suk, et al.
Publicado: (2019)

Joint longitudinal model-based meta-analysis of FEV(1) and exacerbation rate in randomized COPD trials
por: Llanos-Paez, Carolina, et al.
Publicado: (2023)

Utility of FEV(1)/FEV(6) index in patients with multimorbidity hospitalized for decompensation of chronic diseases
por: Komal, Shakeel, et al.
Publicado: (2019)

Forced Expiratory Volume in 6 s (FEV(6)) and FEV(1)/FEV(6) Values as a Viable Alternative for Forced Vital Capacity (FVC) and FEV(1)/FVC Values During Pregnancy in South East Nigeria: A Preliminary Study
por: Nwagha, U, et al.
Publicado: (2014)

Prognostic marker for severe acute exacerbation of chronic obstructive pulmonary disease: analysis of diffusing capacity of the lung for carbon monoxide (D(LCO)) and forced expiratory volume in one second (FEV(1))
por: Choi, Juwhan, et al.
Publicado: (2021)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Oral Dexamethasone vs. Oral Prednisone for Children With Acute Asthma Exacerbations: A Systematic Review and Meta-Analysis
por: Wei, Jienan, et al.
Publicado: (2019)

Association Between Vitamin D Levels and FEV1, Number of Exacerbations, and CAT Score in Stable COPD Patients in Indonesia
por: Soeroto, Arto Yuwono, et al.
Publicado: (2021)

Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension
por: Latus, Heiner, et al.
Publicado: (2015)

Prevalence and characteristics of chronic obstructive pulmonary disease in China with a diagnostic criterion of FEV(1)/FVC less than the lower limit of normal—a reanalysis of Chinese epidemiological survey of COPD (CESCOPD) study
por: Liu, Sha, et al.
Publicado: (2021)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Suspected Pediatric-Onset Common Variable Immune Deficiency (CVID) in a Seven-Year-Old Female With Pulmonary Manifestations
por: Noor, Noshaba, et al.
Publicado: (2022)

Allergen bronchoprovocation: correlation between FEV(1) maximal percent fall and area under the FEV(1) curve and impact of allergen on recovery
por: Durr, Sarah-Marie, et al.
Publicado: (2023)

Inhaled corticosteroids and FEV(1) decline in chronic obstructive pulmonary disease: a systematic review
por: Whittaker, Hannah R., et al.
Publicado: (2019)

Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging
por: Landini, Nicholas, et al.
Publicado: (2023)

Nebulized albuterol delivery is associated with decreased skeletal muscle strength in comparison with metered‐dose inhaler delivery among children with acute asthma exacerbations
por: Burger, Catherine, et al.
Publicado: (2021)

Antibiotic duration and changes in FEV(1) are not associated with time until next exacerbation in adult cystic fibrosis: a single center study
por: Espel, Julia C., et al.
Publicado: (2017)

Wilms Tumor with dilated hypertensive cardiomyopathy, acute myocarditis, pulmonary edema, and heart failure
por: Chung, Jae Min, et al.
Publicado: (2020)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

Acute Kidney Injury and Pediatric Bone Health
por: Hegde, Anisha, et al.
Publicado: (2021)

Factors Associated with the Expression of ACE2 in Human Lung Tissue: Pathological Evidence from Patients with Normal FEV(1) and FEV(1)/FVC
por: Bao, Wuping, et al.
Publicado: (2021)

Comparison of the variability of the annual rates of change in FEV(1) determined from serial measurements of the pre- versus post-bronchodilator FEV(1) over 5 years in mild to moderate COPD: Results of the lung health study
por: Tashkin, Donald P, et al.
Publicado: (2012)

Annual change in FEV(1) in elderly 10-year survivors with established chronic obstructive pulmonary disease
por: Suzuki, Masaru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dum6g8tn2f0piq4acrb73nd3pp